Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ONCO
Onconetix, Inc. Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
0.0847USD+13.539%(+0.0101)136,635,610
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:28:30 AM EDT
0.0791USD+6.032%(+0.0045)3,251,041
After-hours
May 16, 2025 4:58:30 PM EDT
0.0844USD-0.354%(-0.0003)1,011,400
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
03:42PM EST  Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to   PR Newswire
Jan 13, 2022
02:29AM EST  Oncopeptides phase 3 OCEAN study published in the Lancet Haematology   PR Newswire
Jan 5, 2022
02:25AM EST  Oncopeptides announces year-end cash 2021   PR Newswire
Dec 10, 2021
02:44AM EST  Oncopeptides presents new melflufen data at the Annual American Society of   PR Newswire
Nov 24, 2021
02:58AM EST  Oncopeptides publishes Q3 2021 report   PR Newswire
Nov 19, 2021
09:21AM EST  Invitation to presentation of the Q3 2021 results   PR Newswire
Nov 15, 2021
02:59AM EST  Jakob Lindberg appointed CEO of Oncopeptides   PR Newswire
Nov 12, 2021
03:20AM EST  Oncopeptides has announced the Nomination Committee   PR Newswire
Nov 4, 2021
12:56PM EDT  Oncopeptides focuses clinical development efforts to increase cash runway   PR Newswire
Nov 1, 2021
12:55PM EDT  Oncopeptides appoints Annika Muskantor as interim CFO   PR Newswire
Oct 22, 2021
09:36AM EDT  Oncopeptides Withdraws Pepaxto In US   RTTNews
09:34AM EDT  Oncopeptides withdraws Pepaxto(r) in US, scale down organization and focus on   PR Newswire
Oct 15, 2021
11:50AM EDT  Oncopeptides' CFO Anders Martin-Lf will leave the company   PR Newswire
Sep 11, 2021
08:35AM EDT  Oncopeptides presents phase 3 OCEAN study results at the IMW meeting   PR Newswire
Sep 9, 2021
11:20AM EDT  Invitation to webcast for presentation of OCEAN data presented at IMW   PR Newswire
Sep 2, 2021
11:46AM EDT  Regulatory update from US Food and Drug Administration   PR Newswire
Aug 27, 2021
01:57PM EDT  Oncopeptides presents new data from OCEAN and PORT study - abstracts online   PR Newswire
Aug 19, 2021
02:08AM EDT  Oncopeptides publishes report for Q2 2021   PR Newswire
Aug 16, 2021
08:52AM EDT  Oncopeptides' PEPAXTO(r) Receives a Permanent J-Code, Clarifying Reimbursement   PR Newswire
Aug 12, 2021
07:23AM EDT  Invitation to presentation of the Q2 2021 results   PR Newswire
Jul 28, 2021
11:19AM EDT  Regulatory update from US Food and Drug Administration   PR Newswire
Jul 8, 2021
02:19AM EDT  Oncopeptides : Updated Phase 3 OCEAN Study Shows Melflufen Met Primary Endpoint Of Superior PFS   RTTNews
02:09AM EDT  Updated results from phase 3 OCEAN study shows melflufen met primary endpoint   PR Newswire
Jun 30, 2021
02:10AM EDT  Number of shares and votes in Oncopeptides   PR Newswire
May 26, 2021
09:17AM EDT  Bulletin from the Annual General Meeting in Oncopeptides AB (publ)   PR Newswire
02:53AM EDT  Oncopeptides Q1 Loss/Shr SEK 3.45 Vs Loss/Shr SEK 5.37 Year Ago   RTTNews
02:14AM EDT  Oncopeptides publishes report for Q1 2021 and updated dates for the publication   PR Newswire
May 25, 2021
01:21AM EDT  efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma   PR Newswire
May 20, 2021
02:54AM EDT  Oncopeptides AB: Invitation to presentation of the Q1 2021 results   PR Newswire
May 19, 2021
07:26PM EDT  Oncopeptides announces three abstracts accepted by the 2021 American Society of   PR Newswire
06:11PM EDT  Oncopeptides presents clinical abstracts on melflufen at the 2021 American   PR Newswire
May 12, 2021
10:18AM EDT  Oncopeptides Presents New Clinical And Preclinical Melflufen Data At European Hematology Association Meeting   RTTNews
10:16AM EDT  Oncopeptides presents new clinical and preclinical melflufen data at the   PR Newswire
May 5, 2021
07:44AM EDT  Oncopeptides completes patient enrollment in phase 2 PORT study   PR Newswire
Apr 30, 2021
02:36AM EDT  Number of shares and votes in Oncopeptides   PR Newswire
Apr 26, 2021
08:15AM EDT  Oncopeptides Publishes The 2020 Annual Report   RTTNews
03:10AM EDT  Annual General Meeting in Oncopeptides AB (publ)   PR Newswire
Apr 16, 2021
02:23AM EDT  Oncopeptides Submits Application For Conditional Marketing Authorization Of Melflufen In The EU   RTTNews
02:21AM EDT  Oncopeptides submits application for conditional marketing authorization of   PR Newswire
Mar 31, 2021
02:22AM EDT  Number of shares and votes in Oncopeptides   PR Newswire
Mar 22, 2021
07:52AM EDT  Oncopeptides announces that PEPAXTO(r) is included in new Multiple Myeloma   PR Newswire
07:40AM EDT  Oncopeptides Announces National Comprehensive Cancer Network(r) Adds PEPAXTO(r)   PR Newswire
Mar 15, 2021
08:44AM EDT  Oncopeptides Says First Patients In U.S. Being Treated With PEPAXTO   RTTNews
08:42AM EDT  Oncopeptides announces that the first patients in the United States are being   PR Newswire
Mar 8, 2021
02:19AM EST  Oncopeptides strengthens leadership in Europe and opens an Early Access Program   PR Newswire
Mar 1, 2021
07:45AM EST  FDA Approves Oncopeptides PEPAXTO For Patients With Triple-Class Refractory Multiple Myeloma   RTTNews
07:41AM EST  FDA Approves Oncopeptides? PEPAXTO(r) (melphalan flufenamide) for Patients with   PR Newswire
Feb 26, 2021
06:26PM EST  FDA approves Oncopeptides' PEPAXTO(r) ( melphalan flufenamide) for patients   PR Newswire
Feb 18, 2021
02:45AM EST  Oncopeptides AB: Year-end Report 2020   PR Newswire
Dec 21, 2020
10:58AM EST  Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination   PR Newswire
Dec 15, 2020
08:20AM EST  Oncopeptides strengthens its organization by appointing Linda Holmstrm as   PR Newswire
Dec 9, 2020
09:06PM EST  Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma   PR Newswire
Dec 7, 2020
04:12AM EST  Oncopeptides will host a webcast on Wednesday, December 9th at 14:00 (CET) to   PR Newswire
Dec 6, 2020
10:56PM EST  Oncopeptides Presents New Data From Phase 2 ANCHOR Combination Study In Multiple Myeloma At ASH   RTTNews
09:07PM EST  Oncopeptides presents new data from phase 2 ANCHOR combination study in   PR Newswire
Dec 4, 2020
10:16AM EST  Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)   PR Newswire
Nov 30, 2020
02:13AM EST  Number of shares and votes in Oncopeptides   PR Newswire
Nov 24, 2020
09:41AM EST  Program for Oncopeptides virtual Capital Markets Day on November 30 is published   PR Newswire
Nov 19, 2020
02:47AM EST  Oncopeptides: INTERIM REPORT Q3 2020   PR Newswire
Nov 5, 2020
08:34AM EST  Oncopeptides hosts a virtual capital markets day on November 30   PR Newswire
Nov 4, 2020
10:44AM EST  Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation   PR Newswire
Nov 3, 2020
02:15AM EST  Extraordinary General Meeting in Oncopeptides AB (publ)   PR Newswire
Oct 21, 2020
02:41AM EDT  Nomination committee in Oncopeptides established   PR Newswire
Oct 19, 2020
02:52AM EDT  Oncopeptides has submitted an Investigational New Drug application to FDA for   PR Newswire
Oct 14, 2020
12:10PM EDT  Oncopeptides signs (euro) 40 million loan agreement with the EIB   PR Newswire
Oct 12, 2020
02:20AM EDT  With the priority review underway at FDA, Oncopeptides moves forward with   PR Newswire
Oct 1, 2020
02:16AM EDT  Oncopeptides initiates U.S. Expanded Access Program with melflufen in   PR Newswire
Sep 4, 2020
02:20AM EDT  Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN   PR Newswire
Aug 29, 2020
06:35AM EDT  FDA grants Priority Review of melflufen for patients with triple-class   PR Newswire
Aug 26, 2020
02:29AM EDT  Oncopeptides AB: Interim Report Q2 2020   PR Newswire
Aug 7, 2020
02:18AM EDT  Oncopeptides initiates the first study with melflufen outside multiple myeloma   PR Newswire
Aug 4, 2020
09:53AM EDT  Oncopeptides starts the phase 2 PORT study comparing peripheral versus central   PR Newswire
Jul 31, 2020
09:42AM EDT  Number of shares and votes in Oncopeptides   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC